Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy
World Journal of Surgical Oncology · 2024
DOI: 10.1186/s12957-024-03477-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgical Oncology, 2024. Verfasst von Courtney C Sparger und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Miami, Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Axilla, Breast Neoplasms, Sentinel Lymph Node Biopsy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ruth L. Kirschstein Institutional National Research Service Award.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Low false negative rates can be achieved with sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients with clinical N1 (cN1) disease. We examined changes in axillary management and oncologic outcomes in BC patients with cN1 disease receiving NAC.
Methods
BC patients with biopsy proven cN1 disease treated with NAC were selected from our institutional cancer registry (2014–2017). Patients were grouped by axillary management, axillary lymph node dissection (ALND), SLNB followed by ALND, or SLNB alone. Univariable and multivariable survival analysis for recurrence-free survival (RFS) and overall survival (OS) were performed.
Results
81 patients met inclusion criteria: 31 (38%) underwent ALND, 25 (31%) SLNB + ALND, and 25 (31%) SLNB alone. A SLN was identified in 45/50 (90%) patients who had SLNB. ALND was performed in 25/50 (50%) patients who had SLNB: 18 for a + SLNB, 5 failed SLNB, and 2 insufficient SLNs. 25 patients had SLNB alone, 17 were SLN- and 8 SLN+. In the SLNB alone group, 23/25 (92%) patients received adjuvant radiation (RT). 20 (25%) patients developed BC recurrence: 14 distant (70%), 3 local (15%), 2 regional + distant (10%), and 1 contralateral (5%). In the SLNB alone group, there was 1 axillary recurrence in a patient with a negative SLNB who did not receive RT. Univariable survival analysis showed significant differences in RFS and OS between axillary management groups, ALND/SLNB + ALND vs. SLNB alone (RFS: p = 0.006, OS: p = 0.021). On multivariable survival analysis, worse RFS and OS were observed in patients with TNBC (RFS: HR 3.77, 95% CI 1.70–11.90, p = 0.023; OS: HR 8.10, 95% CI 1.84–35.60, p = 0.006).
Conclusions
SLNB alone and RT after NAC in BC patients with cN1 disease who have negative SLNs at surgery provides long-term regional disease control. This analysis provides support for the practice of axillary downstaging with NAC and SLNB alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Miami, Miller School of Medicine, Miami, FL, USA.
- DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
- Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
- Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. sxk1006@med.miami.edu.
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. sxk1006@med.miami.edu.
Förderung
- Ruth L. Kirschstein Institutional National Research Service Award
Zitieren
APA
Sparger, C. C., Hernandez, A. E., Rojas, K. E., Khan, K., Halfteck, G. G., Möller, M., Avisar, E., Goel, N., Crystal, J. S., & Kesmodel, S. B. (2024). Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy. World Journal of Surgical Oncology. https://doi.org/10.1186/s12957-024-03477-4
Vancouver
Sparger CC, Hernandez AE, Rojas KE, Khan K, Halfteck GG, Möller M, et al. Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy. World Journal of Surgical Oncology. 2024. doi:10.1186/s12957-024-03477-4
BibTeX
@article{Sparger2024,
author = {Sparger, Courtney C and Hernandez, Alexandra E and Rojas, Kristin E and Khan, Khadeja and Halfteck, Gili G and Möller, Mecker and Avisar, Eli and Goel, Neha and Crystal, Jessica S and Kesmodel, Susan B},
title = {Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy},
journal = {World Journal of Surgical Oncology},
year = {2024},
doi = {10.1186/s12957-024-03477-4}
}
EUVIMED